| Document |
Document Title |
|
WO/2020/083971A2 |
The present invention relates to novel compounds of general formula (I) with A being A1 or A2, and in which T, X, Y, Ro, R1, R10 and R11 are as defined herein, methods of preparing said compounds, intermediate compounds useful for prepar...
|
|
WO/2020/086728A1 |
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/085373A1 |
The present invention provides a novel compound which has activating activity selective for ERĪ². A compound represented by formula (1) or a salt thereof. (In the formula, R1 represents a cycloalkyl group having 3-8 carbon atoms, an alke...
|
|
WO/2020/080979A1 |
This disclosure relates to new phthalimide and isoindolinone derivatives and other PFKFB3 inhibitors for use in the treatment of diseases. The invention further relates to pharmaceutical compositions containing such PFKFB3 inhibitors, me...
|
|
WO/2020/077197A1 |
The instant invention describes pharmaceutical compositions and dosing regimens comprising radiation therapy and seviteronel with or without dexamethasone, and methods of treating diseases, disorders or symptoms thereof.
|
|
WO/2020/072008A1 |
The object of the present invention is to provide a pharmaceutical composition comprising solid dispersion of selinexor, having enhanced bioavailability and improved dissolution properties. In accordance with the invention, solid dispers...
|
|
WO/2020/063756A1 |
A novel triazole compound of the formula (IV) is provided, it can be used in agriculture, wherein R1 is cyclopropyl and the like; X is -CH2-and the like; each of R4 and R6 is independently hydrogen, fluorine, chlorine, CH3-, etc.; each o...
|
|
WO/2020/057604A1 |
A TLR8 (Toll-like receptor 8) agonist, a compound of the structure shown in formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.
|
|
WO/2020/055507A1 |
Aprotic-protic ionic salt (APS) compositions and methods of using aprotic-protic ionic salt compositions to stabilize nucleic acids at ambient temperatures are provided. Certain aspects provide aprotic-protic ionic salt compositions for ...
|
|
WO/2020/051207A2 |
The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presenc...
|
|
WO/2020/051260A1 |
This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treatin...
|
|
WO/2020/043866A1 |
A compound for use in the treatment of a disease ameliorated by the inhibition of Notum of formula (I): (I)
|
|
WO/2020/046382A1 |
Disclosed are substituted heterocycle compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utili...
|
|
WO/2020/043831A1 |
The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof useful as inhibitors of Cyclophilins and modulators of cyclophilin-like proteins. The invention also relates to uses of said compound...
|
|
WO/2020/041556A1 |
The present invention relates to the discovery of novel N-(substituted)-1H-1,2,4-triazole-3-carboxamide compounds capable of inhibiting DksA activity in a bacteria cell. In certain embodiments, the compounds are capable of killing or wea...
|
|
WO/2020/036134A1 |
The present invention provides a 5-(1,2,4-triazole-5-yl) benzoic acid amide derivative with a superior harmful organism control effect or a salt thereof, and a harmful organism control agent and a manufacturing intermediate that include ...
|
|
WO/2020/036133A1 |
The present invention addresses the problem of providing a superior harmful organism control agent. Provided are the 3-(1H-1,2,4-triazole-1-yl) benzoic acid amide derivative shown in general formula [I] or an agrochemically permissible s...
|
|
WO/2020/010309A9 |
The present invention provides triazole carboxylic acids and related compounds, as well as pharmaceutically acceptable salts thereof, which are useful as glycolate oxidase inhibitors. Pharmaceutical compositions and methods for treating ...
|
|
WO/2020/020851A1 |
The present invention relates to reagents which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said reagents.
|
|
WO/2020/020849A1 |
The present invention relates to reagents which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said reagents.
|
|
WO/2020/021032A1 |
The present invention relates to compounds of the generation (n) dendrimer type or the salts thereof, comprising: a central unit of valency 3 having formula (I), (n-1) inner generation layers consisting of repeat units having formula (II...
|
|
WO/2020/020850A1 |
The present invention relates to reagents which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said reagents.
|
|
WO/2020/018613A1 |
Provided herein are compounds of Formula I, Formula II Formula III which are useful in labeling tissues in a subject (e.g., PET imaging of a subject), for treatment of cancer, and/or for preparing a medicament. Also provided are compound...
|
|
WO/2020/018788A1 |
Disclosed are bifunctional compounds, pharmaceutical compositions containing them, and methods of making and using them to treat diseases and disorders characterized by aberrant protein activity wherein the protein is targeted for degrad...
|
|
WO/2020/011922A1 |
The present invention relates to certain dithiocarbamate compounds of formula (I) comprising a nitrogen containing heterocyclic ring, and exhibiting strong absorption in the visible range of the light spectrum. The compounds of the inven...
|
|
WO/2020/008391A1 |
The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)c
yclobutyl)propane-1-sulfonamide. The present i...
|
|
WO/2020/002634A1 |
The present invention relates to specific nitrogen containing compounds of formulas (I), (II) and (IV) of the present invention, which are suitable to be used in a method to detect alkyne group containing organic compounds by mass spectr...
|
|
WO/2020/006336A1 |
A method of treating or preventing cardiovascular calcification in a subject is described that includes administering to a subject in need thereof a therapeutically effective amount of a nuclear export inhibitor. In particular, the metho...
|
|
WO/2020/006177A1 |
Disclosed herein are small molecule Vascular Adhesion Protein- 1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2019/245393A1 |
The present invention relates to 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives and derivatives of 4-(1-phenyl-7H-[1,2,3]triazol-4-yl)- phenol as new compounds. The subject of the invention is the medical use of 4-(l- p...
|
|
WO/2019/246454A1 |
The present disclosure relates to therapeutic agents that may be useful in treatment and prophylaxis of neurodegenerative disorders and/or neural inflammation.
|
|
WO/2019/238091A1 |
A compound for improving the gene editing specificity and application thereof. Specifically disclosed is a compound represented by formula I or a use of a pharmaceutically acceptable salt thereof. The compound and the pharmaceutically ac...
|
|
WO/2019/240140A1 |
Provided are a method for separating a DAPTAD-containing triazolinedione compound in solid form from a reaction solution, a separated solid triazolinedione compound, and a novel method for producing a triazolinedione compound. A triazoli...
|
|
WO/2019/240142A1 |
Provided is a method for industrially producing a triazolidinedione compound at a high purity and a high yield. A precipitation step for preparing a solution that contains a triazolidinedione compound represented by formula (1) and preci...
|
|
WO/2019/233447A1 |
Provided are compounds of Formula I'-III', as well as their preparation and uses, and pharmaceutical compositions comprising these compounds and their uses as nuclear transport modulators. Provided are also uses of the compounds or pharm...
|
|
WO/2019/232724A1 |
The present invention relates compounds of Formula (I) - (V), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as nuclear transport modulators. The present i...
|
|
WO/2019/235501A1 |
The present invention provides a novel compound which has HDAC2 inhibitory activity. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (In the formula, R1 represents a hydrogen atom, a halogen atom, a s...
|
|
WO/2019/234546A1 |
The present invention relates to antifungal cuticle oil composition comprising Efinaconazole or Tavaborole or Terbinafine or salt thereof in the treatment of onychomycosis. The topical antifungal cuticle oil according to present inventio...
|
|
WO/2019/224667A1 |
The present invention relates indane compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I) or Formula (II), and p...
|
|
WO/2019/218024A1 |
The present invention relates to compounds useful in the modulation of ion channel activity in cells. The invention also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compoun...
|
|
WO/2019/216266A1 |
The present invention addresses the problem of providing a compound capable of forming a cured product having excellent light resistance, heat resistance, etc. The present invention relates to a compound having a structure represented by...
|
|
WO/2019/214467A1 |
A resolution method for axis chiral enantiomers of Lesinurad (2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazo
l-3-ylthio)acetic acid). In said method, inexpensive and readily available quinoline natural products and derivativ...
|
|
WO/2019/210741A1 |
Provided in the present invention are a novel blue light-absorbing compound, the synthesis thereof and an application thereof. The compound of the present invention has high stability and is suitable for high temperature processing condi...
|
|
WO/2019/211463A1 |
The present invention relates to substituted 5-membered nitrogen containing heteroaryl compounds, such as sulfonyl triazoles, where the heteroaryl ring is further substituted, optionally via a linking group such as -NH-, with a cyclic gr...
|
|
WO/2019/212196A1 |
The present invention relates to a composition for preventing or treating neurodegenerative diseases or depression, containing a 2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative as an active ingredient and, more specifically, t...
|
|
WO/2019/209693A1 |
Methods of preparing N-2 alkylated triazoles substantially free from N-1 and N-3 alkylated triazoles are disclosed. The methods include one-step alkylation methods and two-step alkylation methods for the preparation of N-alkylated triazo...
|
|
WO/2019/205687A1 |
Disclosed in the present invention are a phenyl triazole MLL1-WDR5 protein-protein interaction inhibitor (I) and a preparation method therefor; pharmacodynamic tests have proven that the compound of the present invention has strong MLL1-...
|
|
WO/2019/200500A1 |
Disclosed in the present invention is a method for preparing 1,2,4-triazole, comprising using a fluoroborate aryl diazonium salt, a diazoester derivative and an organic nitrile as reaction substrates, using a transition metal as a cataly...
|
|
WO/2019/204447A1 |
Disclosed herein are small molecule inhibitors of platelet function, and methods of using the small molecules to treat diseases, such as platelet hemostasis and thrombosis. In particular, disclosed herein are compounds of Formula (I) and...
|
|
WO/2019/199496A1 |
The present invention generally relates to compounds as a new antibiotic to treat various infections, including infections caused by methicillin-resistant Staphylococcus aureus, vancomycin-intermediate and vancomycin-resistant Staphyloco...
|
